References
- Chinese Pharmacopoeia Commission(2000): Chinese Pharmacopoeia. (Part I).Beijing, Chemical Industry Publisher, pp. 267.
- Gao Suqiang, Fu Dexing, Zhang Hongmei (1999): Advances in the study on the treatment of osteoporosis withHerba Epimedii. and its compound prescriptions.China J Chin Materia Med, 24: 249–251
- Gray TK, Flynn TC, Gray KM, Nabell LM (1987):17 beta-Estradiol acts directly on the clonal osteoblastic cell line UMR106.Proc Natl Acad Sci USA, 84: 6267–6271. [PUBMED], [INFOTRIEVE], [CSA]
- Li Wenkui, Zhang Ruyi, Xiao Peigen (1995):Chemical studies of Epimedium koreanum.. Chin Trad Herbal Drugs 26: 453–455. [CSA]
- Li Qingnan, Liao Jinmin, Wu Tie, Huang Liangfang, Liang Nianci (1996): Epimedium sagittatum. Maxim preventing hormone-induced osteoporosis in rats. Chin Pharm J 31: 467–470.
- Ma Huiping, Jia Zhengping, Ge Xin, He Xiaoying, Chen Keming, Bai Menghai (2002): Studies on the theraputic effect of total flavonoids of Herba Epimedii. on experimental osteoporosis in rats. Huaxi J Pharm 17: 163–167.
- Partridge NC, Alcorn D, Micheelaangeli VP, Ryan G, Martin TJ (1983): Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res 43: 4308–4314. [PUBMED], [INFOTRIEVE]
- Sun P, Zhao J, Wen Y, Pei Y, Zhang G, Wang Z, Cheng Y (1995): Chemical studies of Epimedium koreanum.. J Shenyang Pharm Univ 12: 266–269.
- Wang D, Li F, Gao X, Jiang Z (2001): Effect of Drynaria baronii. rhizome extracts on the proliferation in osteoblast-like UMR 106 cells. Pharm Biol 39: 259–262.